Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 13/20 | 0.90 |
| ▸ | HSP90AB1 | P08238 | 7/20 | 0.90 |
| ▸ | HSP90B1 | P14625 | 5/20 | 0.90 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.90 |
| ▸ | TRAP1 | Q12931 | 5/20 | 0.90 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17771168 | 0.97 | HSP90AA1 (0.86) | HSP90AA1HSP90AB1HSP90B1ERBB2TRAP1 | |
| Pu-H71 SCHEMBL29414148 | 0.95 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1HSP90B1ERBB2TRAP1 | |
| Pu-H71 SCHEMBL1857579 | 0.95 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1HSP90B1ERBB2TRAP1 | |
| SCHEMBL15624878 | 0.92 | HSP90AA1 (0.95) | HSP90AA1HSP90AB1HSP90B1ERBB2TRAP1 | |
| SCHEMBL11909860 | 0.92 | HSP90AA1 (0.79) | HSP90AA1HSP90AB1HSP90B1ERBB2TRAP1 | |
| SCHEMBL17449248 | 0.92 | HSP90AA1 (0.79) | HSP90AA1HSP90AB1HSP90B1ERBB2TRAP1 | |
| SCHEMBL1669649 | 0.92 | HSP90AA1 (0.79) | HSP90AA1HSP90AB1HSP90B1ERBB2TRAP1 | |
| SCHEMBL18203277 | 0.91 | HSP90AA1 (0.78) | HSP90AA1HSP90AB1HSP90B1ERBB2TRAP1 | |
| SCHEMBL18169514 | 0.91 | HSP90AA1 (0.78) | HSP90AA1HSP90AB1HSP90B1ERBB2TRAP1 | |
| SCHEMBL1671215 | 0.91 | HSP90AA1 (0.75) | HSP90AA1HSP90AB1HSP90B1ERBB2TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3091019-A2 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | Sloan Kettering Institute For Cancer Research (US) | 2016-11-09 | — | — | EP | claimed |
| US-20210308285-A1 | HSP90-TARGETED INFLAMMATION AND INFECTION IMAGING AND THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-10-07 | — | — | US | disclosed |
| US-11065350-B2 | HSP90-targeted inflammation and infection imaging and therapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210161902-A1 | EPICHAPEROME INHIBITOR THERAPY FOR TRAUMATIC BRAIN INJURY AND SEQUELAE THEREOF | SAMUS THERAPEUTICS, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210138091-A1 | USES OF LABELED HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2021-05-13 | — | — | US | disclosed |
| CN-111683658-A | Multi-protein complex inhibitor therapy for traumatic brain injury and sequelae thereof | 萨缪斯治疗股份有限公司 | 2020-09-18 | — | — | CN | disclosed |
| EP-3709022-A1 | USES OF LABELED HSP90 INHIBITORS | Sloan-Kettering Institute for Cancer Research (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20200237934-A1 | HSP90-TARGETED INFLAMMATION AND INFECTION IMAGING AND THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER | 2020-07-30 | — | — | US | disclosed |
| US-10617772-B2 | Hsp9O-targeted inflammation and infection imaging and therapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-04-14 | — | — | US | disclosed |
| CN-110996918-A | Oral formulations of HSP90 inhibitors and related methods | 萨缪斯治疗股份有限公司 | 2020-04-10 | — | — | CN | disclosed |
| EP-2729806-B1 | USES OF LABELED HSP90 INHIBITORS | SLOAN-KETTERING INST FOR CANCER RES (US) | 2017-02-22 | — | — | EP | disclosed |
| US-9555137-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-01-31 | — | — | US | disclosed |
| EP-3091019-A2 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | Sloan Kettering Institute For Cancer Research (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20160310497-A1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2016-10-27 | — | — | US | disclosed |
| EP-2486039-B1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SLOAN KETTERING INST CANCER (US) | 2016-06-01 | — | — | EP | disclosed |
| US-9328114-B2 | Hsp90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2016-05-03 | — | — | US | disclosed |
| US-20160015837-A1 | HSP90-TARGETED CARDIAC IMAGING AND THERAPY | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2016-01-21 | — | — | US | disclosed |
| US-20120208806-A1 | Hsp90 Inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2486039-A1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | Sloan Kettering Institute For Cancer Research (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044394-A1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015837-A1 | HSP90-TARGETED CARDIAC IMAGING AND THERAPY | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885HSP90B1 3/4885 |
| US-20120208806-A1 | Hsp90 Inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | HSP90AA1 4/4885HSP90AB1 2/4885HSP90B1 1/4885 |
| US-11065350-B2 | HSP90-targeted inflammation and infection imaging and therapy | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885HSP90B1 3/4885 |
| US-20200237934-A1 | HSP90-TARGETED INFLAMMATION AND INFECTION IMAGING AND THERAPY | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885HSP90B1 3/4885 |
| US-20210161902-A1 | EPICHAPEROME INHIBITOR THERAPY FOR TRAUMATIC BRAIN INJURY AND SEQUELAE THEREOF | HSP90B1, HSP90AB1, HSP90AB2P | HSP90AA1 4/4885HSP90AB1 2/4885HSP90B1 1/4885 |
| US-20160310497-A1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | XDH, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 4/4885HSP90B1 2/4885 |
| US-10617772-B2 | Hsp9O-targeted inflammation and infection imaging and therapy | HSPA9, HSP90AB1, S100A9 | HSP90AA1 5/4885HSP90AB1 2/4885HSP90B1 13/4885 |
| US-20210138091-A1 | USES OF LABELED HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HSP90B1 2/4885 |
| US-20210308285-A1 | HSP90-TARGETED INFLAMMATION AND INFECTION IMAGING AND THERAPY | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885HSP90B1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.